Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 4 I, 1997, Pages 938-945

  Matsuo, Kunihiro ^a   Kumagai, Koichiro ^a   Annoura, Miyuki ^a   Yamanouchi, Yoshio ^a   Handa, Koichi ^a   Nakashima, Yoshiyuki ^a   Hiroki, Tadayuki ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

angiotensin II; losartan; reperfusion arrhythmia; ventricular fibrillation inducing threshold

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; LOSARTAN; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECT; ENZYME INHIBITION; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE;

ALDOSTERONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BIPHENYL COMPOUNDS; CREATINE KINASE; DOGS; IMIDAZOLES; LOSARTAN; MYOCARDIAL REPERFUSION; RECEPTORS, ANGIOTENSIN; TACHYCARDIA, VENTRICULAR; TETRAZOLES; VENTRICULAR FIBRILLATION;

EID: 0030906522     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb05497.x     Document Type: Article

References (39)

1. Hellstrom HR. Coronary artery vasospasm: The likely immediate cause of myocardial infarction. Br Heart J 1979; 41:426-432.
2. Schaffer WA, Cobb LA. Recurrent ventricular fibrillation and models of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 1975; 293:259-262.
3. Elfellah MS, Ogilvie RI. Effect of vasodilator drugs on coronary occlusion and reperfusion arrhythmias in anesthetized dogs. J Cardiovasc Pharmacol 1985; 7:826-832.
4. Sommers HM, Jennings RB. Ventricular fibrillation and myocardial necrosis after transient ischemia. Arch Intern Med 1972; 129:780-789.
5. Reimer KA, Lowe JE, Jennings RB. Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation 1977; 55:181-187.
6. Naito M, Michelson EL, Kmetzo JJ, et al. Failure of antiarrhythmic drugs to prevent experimental reperfusion ventricular fibrillation. Circulation 1981; 63:70-79.
7. Sheehan FH, Epstein SE. Effects of calcium channel blocking agents on reperfusion arrhythmias. Am Heart J 1982; 103:973-977.
8. Balke CW, Kaplinsky E, Michelson EL, et al. Reperfusion ventricular tachyarrhythmias: Correlation with antecedent coronary artery occlusion tachyarrhythmias and duration of myocardial ischemia. Am Heart J 1981; 101:449-456.
9. Packer M, Gottlieb SS, Blum MA. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med 1987; 82(Suppl. 3A):4-10.
10. Pitt B. Natural history of patients with congestive heart failure. Potential role of converting enzyme inhibitors in improving survival. Am J Med 1986; 81(Suppl. 4C):32-35.
11. Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure. A double blind controlled trial. Br Heart J 1984; 52:530-535.
12. Webster MWI, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 54: 305-312.
13. Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: A double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305-312.
14. Linz W, Scholkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor ramipril in ischemic rat hearts. J Cardiovasc Pharmacol 1986; 8(Suppl. 10):S91-S99.
15. de Graeff PA, de Langen CD, van Gilst WH, et al. Protective effects of captopril agonist ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. Am J Med 1988; 84(Suppl. 3A):67-74.
16. Unger T, Ganten D, Lang RE. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol 1986; 8(Suppl. 10):S75-S81.
17. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59(Suppl. A):59A-65A.
18. Kingma JH, de Graeff PA, van Gilst WH, et al. Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in the anesthetized pig. Postgrad Med J 1986; 62(Suppl. 1):159-163.
19. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987; A9:243-260.
20. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252:719-725.
21. Gottliob SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist Losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-1609.
22. DeGraeff PA, van Gilst WH, de Langen GDJ, et al. Concentration-dependent protection by captopril against ischemia-reperfusion injury in the isolated rat heart. Arch Int Pharmacodyn Ther 1986; 280: 181-193.
23. Van Gilst WH, de Graeff PA, Wesseling H, et al. Reduction of reporfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE-498. J Cardiovasc Pharmacol 1986; 8:722-728.
24. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: Mechanisms and prevention. J Mol Cell Cardiol 1984; 16:497-518.
25. Murphy ML, Peng CF, Kane JJ, et al. Ventricular performance and biochemical alteration of regional ischemic myocardium after reperfusion in the pig. Am J Cardiol 1982; 50:821-828.
26. Murakawa Y, Toda I, Nozaki A, et al. Effect of antiarrhythmic drugs on the repetitive extrasystole threshold and the ventricular fibrillation threshold. Cardiology 1989; 76:58-66.
27. Euler DE, Scanlon PJ. Comparative effects of antiarrhythmic drugs on the ventricular fibrillation threshold. J Cardiovasc Pharmacol 1988; 11: 291-298.
28. Moore EN, Spear JF. Ventricular fibrillation threshold. Its physiological and pharmacological importance. Arch Intern Med 1975; 135:446-453.
29. Ertl G, Kloner RA, Alexander RW, et al. Limitation of experimental infarct size by an angiotonsin-converting enzyme inhibitor. Circulation 1982; 65: 40-47.
30. Liang C, Gavras H, Black J, et al. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Circulation 1982; 66:1249-1255.
31. Daniell HB, Carson RR, Ballard KD, et al. Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984; 6:1043-1047.
32. Breshanan GF, Roberts R, Shell WE, et al. Deleterious effects due to hemorrhage after myocardial reperfusion. Am J Cardiol 1974; 33:82-86.
33. Ong L, Reiser P, Coromilas J, et al. Left ventricular function and rapid release of creatinine kinase MB in acute myocardial infarction. N Engl J Med 1983; 309:1-6.
34. McCord JM. Oxygon-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
35. Lefer AM, Peck RC. Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacology 1984; 29:61-69.
36. Hock CE, Ribeiro LGT, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985; 109:222-228.
37. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
38. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122.
39. Ettore A, Claudio B, Bruno M. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332:80-85.